Telomerase based anticancer immunotherapy and vaccines approaches

Vaccine

Volumn 35, Issue 43, 2017, Pages 5768-5775

  Kailashiya, Chahal ^a   Sharma, Hanjabam Barun ^b   Kailashiya, Jyotsna ^c  

^a MADHAV INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^c BANARAS HINDU UNIVERSITY   (India)

Author keywords

Dendritic cell vaccines; GV1001; GX 301; HR2822; hTERT; UV1 vaccine; Vx 001

Indexed keywords

CANCER VACCINE; CAPECITABINE; CELL PENETRATING PEPTIDE; DENDRITIC CELL VACCINE; DNA VACCINE; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; GRNVAC1; GRNVAC2; GX-301 VACCINE; GX301; HR2822; HR2822 VACCINE; TELOMERASE; TEMOZOLOMIDE; TERTOMOTIDE; UNCLASSIFIED DRUG; UV1; UV1 VACCINE; VX-001; VX-001 VACCINE;

ACUTE MYELOID LEUKEMIA; ANGIOGENESIS; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; BREAST CARCINOMA; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DEATH; CELL DIVISION; CHILL; CYTOTOXIC T LYMPHOCYTE; DELAYED HYPERSENSITIVITY; DRUG TOLERABILITY; ENZYME ACTIVITY; ERYTHEMA; FATIGUE; FEVER; FLU LIKE SYNDROME; HLA TYPING; HUMAN; IMMUNOGENICITY; INJECTION SITE PRURITUS; KIDNEY CANCER; LUNG CANCER; MELANOMA; NEUROPROTECTION; NON SMALL CELL LUNG CANCER; NONHUMAN; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CARCINOMA; RASH; REVIEW; T LYMPHOCYTE ACTIVATION; TELOMERE LENGTH; ANIMAL; CELLULAR IMMUNITY; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM; PROCEDURES;

ANIMALS; CANCER VACCINES; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; NEOPLASMS; TELOMERASE;

EID: 85028851046     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2017.09.011     Document Type: Review

References (57)

1. Sekhri, K., Telomeres and telomerase: understanding basic structure and potential new therapeutic strategies targeting it in the treatment of cancer. J Postgrad Med 60 (2014), 303–308.
2. Hayflick, L., How and why we age. Exp Gerontology 33 (1998), 639–653.
3. Buseman, C.M., Wright, W.E., Shay, J.W., Is telomerase a viable target in cancer?. Mutat Res 730 (2012), 90–97.
4. Huo, L.F., Tang, J.W., Huang, J.J., Huang, P.T., Huang, C.F., Kung, H.F., et al. Cancer immunotherapy targeting the telomerase reverse transcriptase. Cell Mol Immunol 3 (2006), 1–11.
5. Jafri, M.A., Ansari, S.A., Alqahtani, M.H., Shay, J.W., Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies. Genome Med, 8, 2016, 69.
6. Agrawal, A., Dang, S., Gabrani, R., Recent patents on anti-telomerase cancer therapy. Recent Pat Anti-Cancer Drug Discovery 7 (2012), 102–117.
7. Vonderheide, R.H., Hahn, W.C., Schultze, J.L., Nadler, L.M., The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10 (1999), 673–679.
8. Lev, A., Denkberg, G., Cohen, C.J., Tzukerman, M., Skorecki, K.L., Chames, P., et al. Isolation and characterization of human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells directed toward the widely expressed tumor T-cell epitopes of the telomerase catalytic subunit. Cancer Res 62 (2002), 3184–3194.
9. Minev, B., Hipp, J., Firat, H., Schmidt, J.D., Langlade-Demoyen, P., Zanetti, M., Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc Natl Acad Sci USA 97 (2000), 4796–4801.
10. Shay, J.W., Wright, W.E., Role of telomeres and telomerase in cancer. Semin Cancer Biol 21 (2011), 349–353.
11. Staff, C., Mozaffari, F., Frodin, J.E., Mellstedt, H., Liljefors, M., Telomerase (GV1001) vaccination together with gemcitabine in advanced pancreatic cancer patients. Int J Oncol 45 (2014), 1293–1303.
12. Kim, B.K., Kim, B.R., Lee, H.J., Lee, S.A., Kim, B.J., Kim, H., et al. Tumor-suppressive effect of a telomerase-derived peptide by inhibiting hypoxia-induced HIF-1alpha-VEGF signaling axis. Biomaterials 35 (2014), 2924–2933.
13. Kim, H., Seo, E.H., Lee, S.H., Kim, B.J., The telomerase-derived anticancer peptide vaccine GV1001 as an extracellular heat shock protein-mediated cell-penetrating peptide. Int J Mol Sci, 17, 2016.
14. Brunsvig, P.F., Aamdal, S., Gjertsen, M.K., Kvalheim, G., Markowski-Grimsrud, C.J., Sve, I., et al. Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunol Immunotherapy: CII 55 (2006), 1553–1564.
15. Brower, V., Telomerase-based therapies emerging slowly. J Natl Cancer Inst 102 (2010), 520–521.
16. Inderberg-Suso, E.M., Trachsel, S., Lislerud, K., Rasmussen, A.M., Gaudernack, G., Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001. Oncoimmunology 1 (2012), 670–686.
17. Park, H.H., Yu, H.J., Kim, S., Kim, G., Choi, N.Y., Lee, E.H., et al. Neural stem cells injured by oxidative stress can be rejuvenated by GV1001, a novel peptide, through scavenging free radicals and enhancing survival signals. Neurotoxicology 55 (2016), 131–141.
18. Middleton, G., Silcocks, P., Cox, T., Valle, J., Wadsley, J., Propper, D., et al. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. Lancet Oncol 15 (2014), 829–840.
19. Kyte, J.A., Gaudernack, G., Dueland, S., Trachsel, S., Julsrud, L., Aamdal, S., Telomerase peptide vaccination combined with temozolomide: a clinical trial in stage IV melanoma patients. Clin Cancer Res: Off J Am Assoc Cancer Res 17 (2011), 4568–4580.
20. Hunger, R.E., Kernland Lang, K., Markowski, C.J., Trachsel, S., Moller, M., Eriksen, J.A., et al. Vaccination of patients with cutaneous melanoma with telomerase-specific peptides. Cancer Immunol Immunotherapy: CII 60 (2011), 1553–1564.
21. Middleton, G., Greenhalf, W., Costello, E., Shaw, V., Cox, T., Ghaneh, P., et al. Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma. Br J Cancer 114 (2016), 510–518.
22. Park, J.K., Kim, Y., Kim, H., Jeon, J., Kim, T.W., Park, J.H., et al. The anti-fibrotic effect of GV1001 combined with gemcitabine on treatment of pancreatic ductal adenocarcinoma. Oncotarget 7 (2016), 75081–75093.
23. Menez-Jamet, J., Gallou, C., Rougeot, A., Kosmatopoulos, K., Optimized tumor cryptic peptides: the basis for universal neo-antigen-like tumor vaccines. Ann Transl Med, 4, 2016, 266.
24. Georgoulias, V., Douillard, J.Y., Khayat, D., Manegold, C., Rosell, R., Rossi, A., et al. A multicenter randomized phase IIb efficacy study of Vx-001, a peptide-based cancer vaccine as maintenance treatment in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics. Clin Lung Cancer 14 (2013), 461–465.
25. Kotsakis, A., Papadimitraki, E., Vetsika, E.K., Aggouraki, D., Dermitzaki, E.K., Hatzidaki, D., et al. A phase II trial evaluating the clinical and immunologic response of HLA-A2(+) non-small cell lung cancer patients vaccinated with an hTERT cryptic peptide. Lung Cancer 86 (2014), 59–66.
26. Ruden, M., Puri, N., Novel anticancer therapeutics targeting telomerase. Cancer Treat Rev 39 (2013), 444–456.
27. Vetsika, E.K., Konsolakis, G., Aggouraki, D., Kotsakis, A., Papadimitraki, E., Christou, S., et al. Immunological responses in cancer patients after vaccination with the therapeutic telomerase-specific vaccine Vx-001. Cancer Immunol Immunotherapy: CII 61 (2012), 157–168.
28. Bolonaki, I., Kotsakis, A., Papadimitraki, E., Aggouraki, D., Konsolakis, G., Vagia, A., et al. Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide. J Clin Oncol: Off J Am Soc Clin Oncol 25 (2007), 2727–2734.
29. Fenoglio, D., Traverso, P., Parodi, A., Tomasello, L., Negrini, S., Kalli, F., et al. A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer. Cancer Immunol Immunotherapy: CII 62 (2013), 1041–1052.
30. Fenoglio, D., Parodi, A., Lavieri, R., Kalli, F., Ferrera, F., Tagliamacco, A., et al. Immunogenicity of GX301 cancer vaccine: four (telomerase peptides) are better than one. Hum Vaccines Immunotherapeutics 11 (2015), 838–850.
31. Lilleby, W., Gaudernack, G., Brunsvig, P.F., Vlatkovic, L., Schulz, M., Mills, K., et al. Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer. Cancer Immunol Immunotherapy: CII 66 (2017), 891–901.
32. Gonzalez, F.E., Gleisner, A., Falcon-Beas, F., Osorio, F., Lopez, M.N., Salazar-Onfray, F., Tumor cell lysates as immunogenic sources for cancer vaccine design. Hum Vaccines Immunotherapeutics 10 (2014), 3261–3269.
33. Vonderheide, R.H., Domchek, S.M., Schultze, J.L., George, D.J., Hoar, K.M., Chen, D.Y., et al. Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res: Off J Am Assoc Cancer Res 10 (2004), 828–839.
34. Dupont, J., Latouche, J.B., Ma, C., Sadelain, M., Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells. Cancer Res 65 (2005), 5417–5427.
35. Aloysius, M.M., Mc Kechnie, A.J., Robins, R.A., Verma, C., Eremin, J.M., Farzaneh, F., et al. Generation in vivo of peptide-specific cytotoxic T cells and presence of regulatory T cells during vaccination with hTERT (class I and II) peptide-pulsed DCs. J Transl Med, 7, 2009, 18.
36. Su, Z., Dannull, J., Yang, B.K., Dahm, P., Coleman, D., Yancey, D., et al. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol 174 (2005), 3798–3807.
37. Nair, S.K., Heiser, A., Boczkowski, D., Majumdar, A., Naoe, M., Lebkowski, J.S., et al. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med 6 (2000), 1011–1017.
38. Khoury, H.J., Collins, R.H., Blum, W., Maness, L., Stiff, P., Kelsey, S.M., et al. Prolonged administration of the telomerase vaccine GRNVAC1 is well tolerated and appears to be associated with favorable outcomes in high-risk acute myeloid leukemia (AML). Blood, 116, 2010, 2190.
39. Sioud, M., Nyakas, M., Saeboe-Larssen, S., Mobergslien, A., Aamdal, S., Kvalheim, G., Diversification of antitumour immunity in a patient with metastatic melanoma treated with ipilimumab and an IDO-silenced dendritic cell vaccine. Case Rep Med, 2016, 9639585.
40. Frolkis, M., Fischer, M.B., Wang, Z., Lebkowski, J.S., Chiu, C.P., Majumdar, A.S., Dendritic cells reconstituted with human telomerase gene induce potent cytotoxic T-cell response against different types of tumors. Cancer Gene Ther 10 (2003), 239–249.
41. Salazar-Onfray, F., Pereda, C., Reyes, D., Lopez, M.N., TAPCells, the Chilean dendritic cell vaccine against melanoma and prostate cancer. Biol Res 46 (2013), 431–440.
42. Mu, X., Sang, Y., Fang, C., Shao, B., Yang, L., Yao, K., et al. Immunotherapy of tumors with human telomerase reverse transcriptase immortalized human umbilical vein endothelial cells. Int J Oncol 47 (2015), 1901–1911.
43. Ding, Z.Y., Wu, Y., Luo, Y., Su, J.M., Li, Q., Zhang, X.W., et al. Mannan-modified adenovirus as a vaccine to induce antitumor immunity. Gene Ther 14 (2007), 657–663.
44. Wang, Y., Zhang, J., Wu, Y., Ding, Z.Y., Luo, X.M., Liu, J., et al. Mannan-modified adenovirus targeting TERT and VEGFR-2: a universal tumour vaccine. Sci Rep, 5, 2015, 11275.
45. Mehrotra, S., Britten, C.D., Chin, S., Garrett-Mayer, E., Cloud, C.A., Li, M., et al. Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer. J Hematol Oncol, 10, 2017, 82.
46. Yang, B., Jeang, J., Yang, A., Wu, T.C., Hung, C.F., DNA vaccine for cancer immunotherapy. Hum Vaccines Immunotherapeutics 10 (2014), 3153–3164.
47. Yan, J., Pankhong, P., Shin, T.H., Obeng-Adjei, N., Morrow, M.P., Walters, J.N., et al. Highly optimized DNA vaccine targeting human telomerase reverse transcriptase stimulates potent antitumor immunity. Cancer Immunol Res 1 (2013), 179–189.
48. Thalmensi, J., Pliquet, E., Liard, C., Escande, M., Bestetti, T., Julithe, M., et al. Anticancer DNA vaccine based on human telomerase reverse transcriptase generates a strong and specific T cell immune response. Oncoimmunology., 5, 2016, e1083670.
49. Masutomi, K., Kaneko, S., Yasukawa, M., Arai, K., Murakami, S., Kobayashi, K., Identification of serum anti-human telomerase reverse transcriptase (hTERT) auto-antibodies during progression to hepatocellular carcinoma. Oncogene 21 (2002), 5946–5950.
50. Kraemer, K., Fuessel, S., Schmidt, U., Kotzsch, M., Schwenzer, B., Wirth, M.P., et al. Antisense-mediated hTERT inhibition specifically reduces the growth of human bladder cancer cells. Clin Cancer Res: Off J Am Assoc Cancer Res 9 (2003), 3794–3800.
51. Herbert, B.S., Gellert, G.C., Hochreiter, A., Pongracz, K., Wright, W.E., Zielinska, D., et al. Lipid modification of GRN163, an N3′ → P5′ thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. Oncogene 24 (2005), 5262–5268.
52. Xu, Y., Goldkorn, A., Telomere and telomerase therapeutics in cancer. Genes, 7, 2016.
53. Chen, Y., Zhang, Y., Functional and mechanistic analysis of telomerase: an antitumor drug target. Pharmacol Therapeutics 163 (2016), 24–47.
54. Bryan, C., Rice, C., Hoffman, H., Harkisheimer, M., Sweeney, M., Skordalakes, E., Structural basis of telomerase inhibition by the highly specific BIBR1532. Structure 23 (2015), 1934–1942.
55. Jager, K., Walter, M., Therapeutic targeting of telomerase. Genes, 7, 2016.
56. Lee, S.H., Danishmalik, S.N., Sin, J.I., DNA vaccines, electroporation and their applications in cancer treatment. Hum Vaccines Immunotherapeutics 11 (2015), 1889–1900.
57. Kotsakis, A., Vetsika, E.K., Christou, S., Hatzidaki, D., Vardakis, N., Aggouraki, D., et al. Clinical outcome of patients with various advanced cancer types vaccinated with an optimized cryptic human telomerase reverse transcriptase (TERT) peptide: results of an expanded phase II study. Ann Oncol: Off J Eur Soc Med Oncol 23 (2012), 442–449.